Literature DB >> 2985995

In vivo activated T lymphocytes in the peripheral blood and cerebrospinal fluid of patients with multiple sclerosis.

D A Hafler, D A Fox, M E Manning, S F Schlossman, E L Reinherz, H L Weiner.   

Abstract

We found an increase in peripheral-blood lymphocytes bearing the T-cell-specific activation antigen Ta1 in 20 of 35 patients with progressive multiple sclerosis, 4 of 18 patients with stable or improving multiple sclerosis, 1 of 17 patients with other neurologic diseases, and 1 of 14 normal controls (P less than 0.0002, Fisher's exact test). No increases in two other markers of T-cell activation, T113 and the interleukin-2 receptor, were found. In the cerebrospinal fluid, patients with progressive multiple sclerosis (pleocytosis, 3.9 +/- 1.6 cells per cubic millimeter) had 42 +/- 3.0 per cent Ta1+ cells. In contrast, patients with other inflammatory central nervous system diseases (36 +/- 13 cells per cubic millimeter) had 9.6 +/- 1.8 per cent Ta1+ cells (P less than 0.01). In patients with other neurologic diseases without inflammation (0.7 +/- 0.16 cells per cubic millimeter), the percentage of Ta1+ cells was equivalent to that in patients with multiple sclerosis (39 +/- 5.4 per cent), although the absolute number was lower. There was a positive correlation between the presence of Ta1+ cells in the spinal fluid and blood of patients with other neurologic diseases, but not patients with multiple sclerosis. Less than 1 per cent of lymphocytes from the spinal fluid of patients with multiple sclerosis expressed interleukin-2 receptors, as compared with 9.8 per cent of cells from subjects with other inflammatory neurologic diseases (P less than 0.01). These results suggest that the T cells in the spinal fluid of patients with multiple sclerosis may be activated by a different mechanism or in a different temporal sequence from that in patients with other nervous system diseases. Furthermore, the increase in Ta1+ cells in the peripheral blood of patients with multiple sclerosis demonstrates systemic immune activation in the disease; monitoring such cells may provide an objective measure of abnormal immunologic activity.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2985995     DOI: 10.1056/NEJM198505303122201

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  67 in total

1.  CD26-mediated signaling for T cell activation occurs in lipid rafts through its association with CD45RO.

Authors:  T Ishii; K Ohnuma; A Murakami; N Takasawa; S Kobayashi; N H Dang; S F Schlossman; C Morimoto
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-02       Impact factor: 11.205

2.  Oligoclonal T cell repertoire in cerebrospinal fluid of patients with inflammatory diseases of the nervous system.

Authors:  D Gestri; L Baldacci; R Taiuti; E Galli; E Maggi; M P Piccinni; M Vergelli; L Massacesi
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-06       Impact factor: 10.154

Review 3.  T lymphocytes in the cerebrospinal fluid of patients with multiple sclerosis.

Authors:  F T Rotteveel; C J Lucas
Journal:  Immunol Res       Date:  1990       Impact factor: 2.829

Review 4.  Potential role of superantigen induced activation of cell mediated immune mechanisms in the pathogenesis of Crohn's disease.

Authors:  J P Ibbotson; J R Lowes
Journal:  Gut       Date:  1995-01       Impact factor: 23.059

5.  Increase in activated T cells and reduction in suppressor inducer T cells in systemic sclerosis.

Authors:  R Gustafsson; T H Tötterman; L Klareskog; R Hällgren
Journal:  Ann Rheum Dis       Date:  1990-01       Impact factor: 19.103

6.  Immunologic abnormalities in chronic fatigue syndrome.

Authors:  N G Klimas; F R Salvato; R Morgan; M A Fletcher
Journal:  J Clin Microbiol       Date:  1990-06       Impact factor: 5.948

Review 7.  Microfluidic sample preparation for diagnostic cytopathology.

Authors:  Albert J Mach; Oladunni B Adeyiga; Dino Di Carlo
Journal:  Lab Chip       Date:  2013-03-21       Impact factor: 6.799

8.  Decreased RORC-dependent silencing of prostaglandin receptor EP2 induces autoimmune Th17 cells.

Authors:  David M Kofler; Alexander Marson; Margarita Dominguez-Villar; Sheng Xiao; Vijay K Kuchroo; David A Hafler
Journal:  J Clin Invest       Date:  2014-05-08       Impact factor: 14.808

9.  Intrathecal production of neopterin in aseptic meningo-encephalitis and multiple sclerosis.

Authors:  S Fredrikson; P Eneroth; H Link
Journal:  Clin Exp Immunol       Date:  1987-01       Impact factor: 4.330

Review 10.  T-cell activation via CD26 and caveolin-1 in rheumatoid synovium.

Authors:  Kei Ohnuma; Hiroshi Inoue; Masahiko Uchiyama; Tadanori Yamochi; Osamu Hosono; Nam H Dang; Chikao Morimoto
Journal:  Mod Rheumatol       Date:  2006       Impact factor: 3.023

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.